FDA Greenlights First‑In‑Class Glioma Imaging Drug Pixclara

The U.S. Food and Drug Administration has just given the nod to Pixclara®, Telix’s FET‑PET imaging drug, marking the first time a radiopharmaceutical of this type can be used to scan gliomas in the United States.

Pixclara (floretyrosine F‑18) is injected into a patient’s bloodstream, where it homes in on the L‑type amino‑acid transporters that tumor cells love to use. Once there, the fluorine‑18 tag emits a faint signal that a PET scanner can pick up, painting a clear picture of whether a brain tumour is truly progressing or simply reacting to prior therapy.

This capability matters because gliomas—responsible for roughly 30% of all central‑nervous‑system tumours and about 80% of malignant brain cancers—are notoriously hard to track. In the U.S. alone, about 24,000 new cases surface each year, and clinicians have long needed a reliable way to separate genuine recurrence from treatment‑induced changes.

“Having Pixclara approved means doctors across the country can finally rely on a PET‑based test that’s already baked into international guidelines like the NCCN,” said Kevin Richardson, CEO of Telix Precision Medicine. “It gives us more certainty, and ultimately, better treatment decisions for patients of any age.”

Experts in the field echoed that sentiment. Kelly Sitkin, president of the American Brain Tumor Association, noted that the drug will complement MRI, offering a sharper view of tumour activity. Likewise, Dr. Patrick Wen of Mass General Brigham praised the high diagnostic accuracy, calling it “a very positive step forward for brain cancer imaging and treatment planning.”

Pixclara isn’t just a stand‑alone product; it’s part of Telix’s broader theranostics platform, which pairs precision diagnostics with targeted therapies. The company already markets Illuccix® and Gozellix® in multiple countries and is advancing several late‑stage therapeutic candidates in prostate, glioblastoma, and kidney cancers.

Beyond glioma, Telix is testing Pixclara in a Phase 3 trial to see if it can also help spot brain metastases, potentially widening its utility even further.

With the FDA’s stamp of approval, patients—whether a toddler just a month old or an adult navigating recurrent disease—can now access this cutting‑edge imaging tool, filling a gap that has existed for far too long.